Summary of "PAIN! Physiology - The Ascending Pathway, Descending Pain Pathway and the Substantia Gelatinosa"

Overview

This summary explains how pain signals travel from an injured body part to the brain (the ascending pathway) and how the brain can modulate or inhibit those signals (the descending pathway). It focuses on the dorsal horn region of the spinal cord called the substantia gelatinosa and the chemical mediators involved.

Key anatomical areas

Peripheral tissue at the injury site (example: right palm)
Peripheral sensory (first‑order) neurons → dorsal horn of the spinal cord
Substantia gelatinosa (dorsal horn) — described as the “gate” for pain transmission
Spinothalamic tract (anterolateral system: lateral and anterior spinothalamic tracts)
Thalamus (relay station)
Somatosensory cortex (postcentral gyrus) — pain is perceived here; mapping is contralateral (a right‑hand stimulus is perceived in the left somatosensory cortex)
Brainstem structures involved in descending control: periaqueductal gray (PAG) in the midbrain and nucleus raphe magnus (NRM) in the medulla; descending serotonergic/noradrenergic neurons are also involved

Ascending (pain transmission) — stepwise summary

Tissue injury (e.g., right palm) → damaged cells release inflammatory mediators (noted in the video subtitles: prostaglandins, “PG”).
Prostaglandins sensitize/activate peripheral nociceptive sensory nerve fibers.
Action potential travels along the peripheral nerve to the dorsal root entry of the spinal cord — this fiber/axon is the first‑order neuron.
The first‑order neuron synapses in the dorsal horn (substantia gelatinosa) and releases neurotransmitters (substance P is highlighted).
The second‑order neuron in the dorsal horn is activated, decussates (crosses to the opposite side), then ascends in the spinothalamic tract through the spinal cord and brainstem to the thalamus.
In the thalamus the second‑order neuron synapses on a third‑order neuron.
The third‑order neuron projects to the somatosensory cortex (contralateral), where the location and perception of pain are interpreted.

Descending (pain modulation/inhibition) — stepwise summary

Higher centers (including PAG in the midbrain) initiate descending control when modulation is needed.
PAG neurons project to brainstem nuclei such as the nucleus raphe magnus (NRM).
NRM (and related brainstem pathways) send descending monoaminergic fibers (serotonergic and/or noradrenergic) down to the dorsal horn of the spinal cord.
In the substantia gelatinosa these descending fibers:
- Directly inhibit presynaptic first‑order terminals, decreasing release of substance P.
- Activate local inhibitory interneurons (an interneuron described in the subtitles as an opioid interneuron).
The activated interneuron releases endogenous opioids (encephalins/enkephalins), which:
- Inhibit presynaptic neurotransmitter (substance P) release.
- Inhibit postsynaptic depolarization of second‑order neurons.
Result: reduced ascending pain transmission — a gating effect that limits how much nociceptive input reaches conscious perception.

Important chemical mediators

Prostaglandins (PG): inflammatory mediators that sensitize nociceptors
Substance P: neurotransmitter released by first‑order neurons to activate second‑order neurons in the dorsal horn
Serotonin (5‑HT) and noradrenaline (norepinephrine): descending modulatory neurotransmitters from brainstem pathways
Enkephalins/endorphins (endogenous opioids): released by local interneurons in the substantia gelatinosa to inhibit pain transmission

Key lessons / takeaways

Pain perception is produced in the brain (somatosensory cortex); the main pain pathway is largely contralateral because it crosses in the spinal cord.
The dorsal horn/substantia gelatinosa acts as a “gate” where ascending nociceptive signals can be modulated.
Both local synaptic mechanisms (e.g., substance P release) and descending brainstem systems (PAG → brainstem → dorsal horn) determine how much pain signal reaches conscious perception.
Endogenous opioids and monoaminergic descending pathways are physiological mechanisms for pain inhibition; this underlies some clinical pain interventions and explains how opioid drugs alter pain signaling.

Notes about terminology (from subtitles)

The video uses terms such as “substantia gelatinosa,” “periaqueductal gray,” “nucleus raphe magnus,” “spinothalamic tract,” “substance P,” “prostaglandins,” and “encephalin/enkephalin.” Some auto‑generated subtitles contained misspellings or abbreviations (for example, “substantial gelatinosa” should be “substantia gelatinosa”; “peri‑aquiductal” → periaqueductal).